Narcos

About Us

WHO WE ARE

MDA Pharmaceuticals was founded in 2009 and is a member of the JUNO Pharmaceutical group. MDA Pharmaceuticals continues to invest heavily in business development and is now emerging as a leading Canadian supplier of generic products focused in the hospital and specialty care market. Our current product portfolio is continuing to expand and promotes niche generic molecules with a well targeted pipeline of products near patent expiry.

OUR BOARD & ADVISORS

MDA's board and advisors are private. Through the expertise these members share, MDA's growth is efficient and targeted. Their insight from the pharmaceutical, technology and device industries continues to be invaluable to success.

BoardOfDirectors
Michel Photo

Michel Charbonneau

CEO

Michel Charbonneau has over 30 years of experience in the pharmaceutical industry, with a strong record of commercial and operational leadership. He has developed an extensive knowledge of the pharmaceutical industry and has demonstrated an ability to build and grow businesses. He previously held leadership positions at Glaxo Canada, Ross Laboratories, and Lederle in addition to worldwide and Quebec-based generic manufacturers such as Mayne Pharma, Uman pharma Canada and Omega Laboratories.

Michel’s exceptional leadership, expertise with strategic planning, marketing and sales, as well as his knowledge of the most efficient partnering strategies, will be a great contribution to MDA Pharmaceuticals in establishing a Canadian platform. Michel developed a keen interest and established a solid track record in the field of oncology. During his tenure he developed and implemented a strategic business plan which enabled the company to become the country’s leading generic oncology supplier.

Michel will continue to focus on the development of a rapidly growing product pipeline and will establish a commercial presence in Canada which will ensure MDA continues to find niche opportunities to better serve Canadians and the Canadian health-care system.